Murine monoclonal glutamic acid decarboxylase (GAD)65 antibodies recognize autoimmune-associated GAD epitope regions targeted in patients with type 1 diabetes mellitus and Stiff-man syndrome

1996 ◽  
Vol 33 (3) ◽  
pp. 225-231 ◽  
Author(s):  
B. Ziegler ◽  
M. Schlosser ◽  
F. Lühder ◽  
M. Strebelow ◽  
P. Augstein ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Glutamic Acid ◽  
Type 1 Diabetes Mellitus ◽  
Glutamic Acid Decarboxylase ◽  
Acid Decarboxylase ◽  
Gad 65 ◽  
Stiff Man Syndrome ◽  
Gad 65 Antibodies

Immune reactivity to glutamic acid decarboxylase 65 in stiff-man syndrome and type 1 diabetes mellitus

The Lancet ◽  
2000 ◽  
Vol 356 (9223) ◽  
pp. 31-35 ◽  
Author(s):  
Tobias Lohmann ◽  
Mohammed Hawa ◽  
R David G Leslie ◽  
Russell Lane ◽  
Jean Picard ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Glutamic Acid ◽  
Type 1 Diabetes Mellitus ◽  
Glutamic Acid Decarboxylase ◽  
Acid Decarboxylase ◽  
Immune Reactivity ◽  
Stiff Man Syndrome ◽  
Glutamic Acid Decarboxylase 65

scholarly journals Time-resolved Fluorometric Assay for Detection of Autoantibodies to Glutamic Acid Decarboxylase (GAD65)

2003 ◽  
Vol 49 (6) ◽  
pp. 908-915 ◽  
Author(s):  
Matti Ankelo ◽  
Annette Westerlund-Karlsson ◽  
Jorma Ilonen ◽  
Mikael Knip ◽  
Kaisa Savola ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Glutamic Acid ◽  
Type 1 Diabetes Mellitus ◽  
Glutamic Acid Decarboxylase ◽  
Acid Decarboxylase ◽  
Serum Samples ◽  
Analytical Range ◽  
Radiobinding Assay

Abstract Background: Type 1 diabetes mellitus results from destruction of the pancreatic insulin-producing beta cells by a chronic autoimmune process. Methods are needed for the detection of circulating autoantibodies to glutamic acid decarboxylase (GAD65), a major marker of this process. Methods: Streptavidin-coated microtiter plates were incubated with biotinylated GAD65, and after incubation with serum samples from patients with type 1 diabetes mellitus and control individuals, europium-labeled GAD65 was added. After washing steps, the delayed fluorescence was measured in duplicate in a fluorometer. Samples collected from 100 patients with newly diagnosed type 1 diabetes mellitus and 100 healthy controls were measured by the new assay and by a radiobinding assay. Results: The detection limit of the new assay was 1.49 WHO units/mL, the calibration curve was linear to 4 140 WHO units/mL, and no hook effect was observed up to 41 400 WHO units/mL. The intraassay CV was 2.1–6.3% over the calibration range. For patient serum samples, the intraassay, interassay, and total CVs were 5.4–7.0%, 9.8–13%, and 12–14%, respectively. Compared with conventional radioimmunologic methods, the analytical range was broader and the analysis time required to perform the measurements was shorter. At a cutoff with 99% specificity, the new assay and the radiobinding assay were positive in 71 and 67 patients, respectively. Conclusions: The new assay provides a rapid and sensitive nonradioactive method applicable for large-scale screening for beta-cell autoimmunity. It has a broad linear analytical range, is easy to perform and automate, and has sensitivity and specificity comparable to those for the conventional radioisotope assay.

Sign in / Sign up

Export Citation Format

Share Document